华东医药(000963.SZ)：控股子公司产品纳入突破性治疗品种名单

Core Viewpoint - East China Pharmaceutical (000963.SZ) announced that its subsidiary, Zhejiang Daor Biotechnology Co., Ltd., has developed a first-in-class (FIC) long-acting tri-target agonist, DR10624, which has been included in the list of breakthrough therapies by the National Medical Products Administration (NMPA) for the treatment of severe hypertriglyceridemia (sHTG) [1] Group 1 - The long-acting tri-target agonist DR10624 targets three receptors: Fibroblast Growth Factor 21 Receptor (FGF21R), Glucagon Receptor (GCGR), and Glucagon-like Peptide-1 Receptor (GLP-1R) [1]